Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients

[1]  N. Kröger,et al.  Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. , 2002, Blood.

[2]  B. Barlogie,et al.  Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Craddock,et al.  Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. , 2002, Blood.

[4]  H. Goldschmidt,et al.  Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. , 2001, Blood.

[5]  H. Goldschmidt,et al.  Angiogenesis in hematologic malignancies , 2001, Annals of Hematology.

[6]  B. Barlogie,et al.  Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. , 2001, Blood.

[7]  G. Gahrton,et al.  Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–98 at European Group for Blood and Marrow Transplantation centres , 2001, British journal of haematology.

[8]  H. Goldschmidt,et al.  Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT) , 2001, Bone Marrow Transplantation.

[9]  H. Goldschmidt,et al.  High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  G. Juliusson,et al.  Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. , 2000, British journal of haematology.

[11]  H. Ludwig,et al.  Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  G Muller,et al.  Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. , 2000, Blood.

[13]  S. Rajkumar,et al.  A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. , 2000, Cancer treatment reviews.

[14]  A. Chott,et al.  Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization , 2000, British journal of haematology.

[15]  A. Dispenzieri,et al.  Thalidomide in the treatment of relapsed multiple myeloma. , 2000, Mayo Clinic proceedings.

[16]  G. van Kaick,et al.  Funktioelle Magnetresonanztomographie in Diagnostik und Therapiemonitoring beim Multiplen Myelom , 2000, Der Radiologe.

[17]  Y. Hattori,et al.  [Bone marrow angiogenesis in multiple myeloma: new insights into the pathogenesis, and development of a new therapeutic approach]. , 2000, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[18]  Levi,et al.  Therapy with thalidomide in refractory multiple myeloma patients — the revival of an old drug , 2000, British journal of haematology.

[19]  B. Barlogie,et al.  Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.

[20]  E. Holmberg,et al.  Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades , 1999, European journal of haematology.

[21]  J. Baars,et al.  Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first‐line treatment in untreated multiple myeloma , 1999, British journal of haematology.

[22]  M. Gore,et al.  A randomized trial of maintenance interferon following high‐dose chemotherapy in multiple myeloma: long‐term follow‐up results , 1998, British Journal of Haematology.

[23]  B. Barlogie,et al.  Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. , 1997, Blood.

[24]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[25]  B. Barlogie,et al.  Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. , 1995, Blood.

[26]  M. Dimopoulos,et al.  The treatment of multiple myeloma. , 1994, The New England journal of medicine.

[27]  W. Gregory,et al.  Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Vesole,et al.  High-dose therapy in multiple myeloma. , 2003, Blood.

[29]  A. Levis,et al.  Low-dose of thalidomide in the treatment of refractory myeloma. , 2000, Haematologica.

[30]  B. Barlogie,et al.  Total therapy with tandem transplants for newly diagnosed multiple myeloma. , 1999, Blood.

[31]  B. Barlogie,et al.  High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. , 1994, Blood.